IMMX · NASDAQ · Biotechnology

Immix Biopharma (IMMX)

Developing BCMA-targeted CAR-T therapy for relapsed or refractory AL amyloidosis.

$12.81
After hours−0.00 (−0.01%)
At close$12.81(+2.73%)